Absci Corporation (Nasdaq: ABSI) reported interim Phase 1 data from its first-in-human HEADLINE trial of ABS-201, an investigational antibody targeting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE